The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.
This trial phase represents an early or specialized stage of clinical development.
This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.
Eli Lilly and Company (LLY) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.